Michael J. McElhaugh
Board Member
Arbutus Biopharma Corp (ABUS)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Michael J. McElhaugh
Michael J. McElhaugh is recorded as COO, CEO and Board Member at Arbutus Biopharma Corp (ABUS). Arbutus Biopharma Corp reported in an 8-K filed February 25, 2025 that Michael J. McElhaugh resigned as Interim President and Chief Executive Officer, effective February 24, 2025. Arbutus Biopharma Corp reported in an 8-K filed February 25, 2025 that Michael J. McElhaugh resigned as member of the Board of Directors, effective February 24, 2025. Arbutus Biopharma Corp reported in an 8-K filed January 4, 2024 that Michael J. McElhaugh was appointed Interim President and Chief Executive Officer, effective January 1, 2024. Equibles holds 5 filed executive changes naming Michael J. McElhaugh; each is listed under recent activity with its source filing. The proxy statement of Arbutus Biopharma Corp reports total compensation of $1,315,235 for Michael J. McElhaugh in fiscal 2022, including a base salary of $448,750. Disclosed compensation is on record for 3 fiscal years.
“Ms. Androski succeeds Michael J. McElhaugh, who ceased serving as the Company's Interim President and Chief Executive Officer concurrent with Ms. Androski's appointment as President and Chief Executive Officer.”
“On February 24, 2025, all of the members of the Board of Directors (the "Board") of Arbutus Biopharma Corporation (the "Company") resigned from the Board and all committees thereof, effective immediately: ... (ii) Michael J. McElhaugh;”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2024-01-01–present
-
Current
2024-01-01–present
-
Current
Start not stated–present
-
2024-05-28–2025-02-24
-
2024-01-01–2025-02-24
-
Arbutus Biopharma Corp (ABUS)
Proxy statement
Start not stated–2022-04-11
Last confirmed by a filing; no departure on record
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Arbutus Biopharma Corp
Other people whose current roles at this company are on record from its filings.
- Lindsay Androski CEO, Chairman, Board Member
- Mark J. Murray CEO
- Tuan Nguyen CFO
- Michael McElhaugh COO
- Mike McElhaugh COO
- J. Christopher Naftzger General Counsel
- Anuj Hasija Board Member
- Eric Venker, M.D., Pharm.D. Board Member
- Frank Torti, M.D. Board Member
- Joseph Bishop Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2022 | Arbutus Biopharma Corp (ABUS) | Chief Operating Officer | $448,750 | $1,315,235 |
| 2021 | Arbutus Biopharma Corp (ABUS) | Chief Operating Officer | — | — |
| 2020 | Arbutus Biopharma Corp (ABUS) | Chief Business Officer | $415,000 | $1,087,791 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.